Liang Qu

Liang Qu

Auto-generated profile, based on publicly available information

Liang Qu

Frontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
LQLiang Qu
Liang Qu
ZYZongyi Yi
Zongyi Yi
SZShiyou Zhu
Shiyou Zhu
CWChunhui Wang
Chunhui Wang
ZCZhongzheng Cao
Zhongzheng Cao
WWWensheng Wei
Wensheng Wei

1 June 2015 in Antiviral Research
Verified
Journal Article
Closed access
YSYanhui Song
Yanhui Song
LQLiang Qu
Liang Qu
HWHaoyi Wang
Haoyi Wang
LWLin Wei
Lin Wei
YDYuansu Dong
Yuansu Dong
Sidong XiongSidong Xiong
Sidong Xiong

10 February 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ZYZongyi Yi
Zongyi Yi
LQLiang Qu
Liang Qu
HTHuixian Tang
Huixian Tang
ZLZhiheng Liu
Zhiheng Liu
YLYing Liu
Ying Liu
WWWensheng Wei
Wensheng Wei

24 July 2025 in Cell Reports Medicine
Verified
Journal Article
Open access
YWYanyan Wang
Yanyan Wang
LLLiangru Lin
Liangru Lin
XWXinyue Wang
Xinyue Wang
JLJing Li
Jing Li
QPQian Pan
Qian Pan
LQLiang Qu
Liang Qu
Chimeric antigen receptor (CAR) T cell therapy has shown promise in treating hematologic malignancies, but it still faces challenges, including high costs, a time-consuming manufacturing process, and the necessity of lymphodepletion. Here, we generate circular RNAs (circRNAs) encoding CAR proteins, referred to as circRNACAR, which mediates remarkable tumor killing in human primary T cells. We demonstrate that circRNACAR, delivered with immunocyte-tropic lipid nanoparticles (LNPs), can form in vivo panCAR cells (CAR-T, CAR-natural killer [NK], and CAR-macrophage), significantly inhibit tumor growth, and reshape the tumor microenvironment in mice. Importantly, combining in vivo panCAR with circRNA-based vaccines encoding the corresponding HER2 antigens exhibits synergistically enhanced anti-tumor immunity. Notably, circRNACAR can in return boost the level of vaccination-elicited HER2-specific antibodies, mediating effective killing of tumor cells by macrophages. In combination with vaccination, in vivo panCAR demonstrates a synergistic enhancement of anti-tumor immunity across various mouse models, thereby establishing a framework for the synergistic in vivo panCAR-VAC immunotherapy.

25 September 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
LQLiang Qu
Liang Qu
ZYZongyi Yi
Zongyi Yi
SZShiyou Zhu
Shiyou Zhu
CWChunhui Wang
Chunhui Wang
ZCZhongzheng Cao
Zhongzheng Cao
WWWensheng Wei
Wensheng Wei

7 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YWYanyan Wang
Yanyan Wang
LLLiangru Lin
Liangru Lin
XWXinyue Wang
Xinyue Wang
JLJing Li
Jing Li
JYJie Yin
Jie Yin
LQLiang Qu
Liang Qu
Chimeric Antigen Receptor (CAR) T cell therapy has shown promise in treating hematologic malignancies. However, it is limited to individualized cell therapy and faces challenges, including high costs, extended preparation time, and limited efficacy against solid tumors. Here, we generated circular RNAs (circRNAs) encoding Chimeric Antigen Receptor (CAR) transmembrane proteins, referred to as circRNA CAR , which mediated remarkable tumor killing in both T cells and macrophages. In addition, macrophages exhibited efficient phagocytosis of tumor cells and pro-inflammatory polarization induced by circRNA CAR in vitro . We demonstrated that circRNA CAR , delivered with immunocyte-tropic lipid nanoparticles (LNPs), significantly inhibited tumor growth, improved survival rates and induced a pro-inflammatory tumor microenvironment in mice. Importantly, the combination of circRNA Anti-HER2-CAR and circRNA-based cancer vaccines encoding the corresponding transmembrane HER2 antigen, termed circRNA HER2 , exhibited synergistically enhanced anti-tumor activity. This proof-of-concept study demonstrated that the combination of circRNA-based in vivo CAR and vaccines, termed in vivo CAR-VAC, holds the potential to become an upgraded off-the-shelf immunotherapy.